WU NK 101
Alternative Names: W NK; WU-NK-101Latest Information Update: 26 Jun 2024
At a glance
- Originator WUGEN
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
- Phase I Colorectal cancer; Head and neck cancer
- Preclinical Malignant melanoma
Most Recent Events
- 21 May 2024 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Refractory metastatic disease, Late-stage disease) in USA (IV) (NCT05674526)
- 21 May 2024 Phase-I clinical trials in Head and neck cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT05674526)
- 09 Dec 2023 Pharmacodynamics data from preclinical studies in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)